Nature Medicine:一次治疗有望持久缓解糖尿病

2016-05-25 唐凤 中国科学网

根据5月23日《自然—医学》在线发表的一篇论文,给小鼠和大鼠注射一次针对大脑调节血糖回路的激素,可以长久缓解糖尿病。

根据5月23日《自然—医学》在线发表的一篇论文,给小鼠和大鼠注射一次针对大脑调节血糖回路的激素,可以长久缓解糖尿病


根据5月23日《自然—医学》在线发表的一篇论文,给小鼠和大鼠注射一次针对大脑调节血糖回路的激素,可以长久缓解糖尿病。虽然这种一次性治疗方法只在拥有轻度糖尿病的啮齿动物上有效,并且具体机制尚不清楚,但这种疗法涉及了一种在人类大脑中天然存在的激素,意味着这些发现有望在临床上治疗糖尿病。

II型糖尿病的特点是血糖病理性的升高。早期研究显示,在小鼠的外周血液系统中注射成纤维细胞生长因子1(FGF1,一种参与了多种生物过程的激素),有着很强的抗糖尿病作用。然而达到这种效果需要多次注射大量激素,并且无法做到持久缓解糖尿病。

美国西雅图华盛顿大学Michael Schwartz和研究团队发现,给患有II型糖尿病的小鼠和大鼠的大脑中注射一次FGF1,可以让这些动物的血糖水平在接下来至少4个月中保持正常。这种持久的抗糖尿病效果不受食物摄入或者体重的影响,这表明这种血糖水平的改善和体重减轻无关。该治疗方法在由饮食引发的肥胖小鼠和遗传引发的肥胖小鼠中都有效,并且在遗传引发的肥胖大鼠中也有效。

这些结果表明大脑可以对全身的血糖信号传导产生强有力的作用。不过研究者指出,需要进一步探索FGF1可能带来的大脑结构的变化。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881066, encodeId=f6851881066a0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 24 06:43:00 CST 2016, time=2016-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773549, encodeId=08a31e7354944, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jan 10 17:43:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858677, encodeId=6e2218586e7d0, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon May 08 12:43:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88150, encodeId=18fa881504e, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:41:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577474, encodeId=06e615e7474eb, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri May 27 05:43:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606924, encodeId=2e2e160692476, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 27 05:43:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-06-24 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1881066, encodeId=f6851881066a0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 24 06:43:00 CST 2016, time=2016-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773549, encodeId=08a31e7354944, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jan 10 17:43:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858677, encodeId=6e2218586e7d0, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon May 08 12:43:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88150, encodeId=18fa881504e, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:41:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577474, encodeId=06e615e7474eb, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri May 27 05:43:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606924, encodeId=2e2e160692476, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 27 05:43:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2017-01-10 kalseyzl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1881066, encodeId=f6851881066a0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 24 06:43:00 CST 2016, time=2016-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773549, encodeId=08a31e7354944, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jan 10 17:43:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858677, encodeId=6e2218586e7d0, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon May 08 12:43:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88150, encodeId=18fa881504e, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:41:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577474, encodeId=06e615e7474eb, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri May 27 05:43:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606924, encodeId=2e2e160692476, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 27 05:43:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2017-05-08 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1881066, encodeId=f6851881066a0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 24 06:43:00 CST 2016, time=2016-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773549, encodeId=08a31e7354944, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jan 10 17:43:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858677, encodeId=6e2218586e7d0, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon May 08 12:43:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88150, encodeId=18fa881504e, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:41:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577474, encodeId=06e615e7474eb, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri May 27 05:43:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606924, encodeId=2e2e160692476, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 27 05:43:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-06-02 沉心多思

    好文章,得多学习了!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1881066, encodeId=f6851881066a0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 24 06:43:00 CST 2016, time=2016-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773549, encodeId=08a31e7354944, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jan 10 17:43:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858677, encodeId=6e2218586e7d0, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon May 08 12:43:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88150, encodeId=18fa881504e, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:41:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577474, encodeId=06e615e7474eb, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri May 27 05:43:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606924, encodeId=2e2e160692476, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 27 05:43:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1881066, encodeId=f6851881066a0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 24 06:43:00 CST 2016, time=2016-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773549, encodeId=08a31e7354944, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jan 10 17:43:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858677, encodeId=6e2218586e7d0, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon May 08 12:43:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88150, encodeId=18fa881504e, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:41:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577474, encodeId=06e615e7474eb, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri May 27 05:43:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606924, encodeId=2e2e160692476, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 27 05:43:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]

相关资讯

Cardiovasc Diabetol:糖尿病慢性肾病患者,应用ARB优于ACEI

背景:当代指南推荐血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体拮抗剂(ARB)治疗高血压合并糖尿病。然而,比较亚洲糖尿病患者应用ACEI和ARB对终末期肾脏疾病(ESRD)和发生主要不良心血管事件(MACE)影响的研究较少。方法:研究者应用台湾糖尿病患者纵向队列的数据,进行一项以人群为基础的动态队列研究。采用倾向评分加权方法比较糖尿病患者应用ACEI和ARB对终末期肾病和MACE发生风险的影

Diabetes Care:糖尿病患者心血管风险预测新因素:NT-proBNP和肌钙蛋白T

心血管疾病(CVD)是在糖尿病中发病率和死亡率的主要原因;然而,心血管疾病风险的异质性已成为糖尿病研究的一个重要原因,为改善糖尿病危险分层提供了一个令人信服的理由。研究人员假设N端脑钠肽激素原(NTproBNP)和高灵敏度的肌钙蛋白T可以提高超出常用风险标记物CVD的风险分层,CVD的风险在糖尿病中是异质性的。在社区动脉粥样硬化风险研究(ARIC)中,有8402名之前没有CVD的参与者(1996-

预知5年后你是否患上糖尿病?

一分钟出结果,提前预知健康风险。中科院合肥研究院的一项产品,有望改写糖尿病检测与治疗历史—— 如今,糖尿病已成为人类的心头大患。资料显示,2013年全球约3.82亿成年人患有糖尿病,其中我国糖尿病患者人数位列全球之首。 提前预知患糖尿病的风险,成为预防和治疗糖尿病的关键。然而,饿着肚子、抽血、数小时的漫长等待……这些不快却又必不可少的传统糖尿病检测程序,令很多人不胜其烦。 如今,一项来自中科

Diabetes Care:糖尿病发病时越年轻,死亡率越高

该研究比较了354例在15-30岁之间(T2DM15-30)被诊断为T2DM的患者并发症的患病率,并匹配了在40-50岁(T2DM40-50)之间被诊断为T2DM的1062例患者。还在覆盖更大范围的发病年龄的15238例患者中,根据其发病年龄检测了标准化死亡率比(SMRs)。研究人员根据一个标准化协议,对并发症状态进行了评估,并从电子数据库中提取数据。生存状态通过链接到澳大利亚国家死亡指数数据进行

Diabetologia:为什么长期规律运动可降低民众患糖尿病风险?

明尼苏达州大学的Lisa S Chow博士和同事们发现,更高水平的心肺适能可显著降低成人患前驱糖尿病和糖尿病的风险,他们指出,通过规律体育锻炼可降低民众患前驱糖尿病和糖尿病的风险。研究发表在Diabetologia。Chow博士表示,许多既往研究显示通过运动维持或增加心肺适能的成年人相比不运动的成年人而言患糖尿病、代谢异常疾病、心血管疾病和心血管疾病死亡的风险更低。然而,这些既往研究得出的结论十分

Diabetes Care:长期强化血糖控制能否降低糖尿病患者的心血管疾病风险?

在控制糖尿病患者心血管风险行为(ACCORD)试验中,2型糖尿病和其他心血管危险因素的参与者进行约4年的强化 vs 标准血糖控后对复合心血管预后具有中性作用,增加了心血管和总死亡率,并减少非致死性心肌梗死。强化的结果在延长的随访期间进行了分析。所有幸存的ACCORD参与者都被应邀参加ACCORD后续(ACCORDION)的研究,在此期间,研究人员根据参与者的医疗保健提供者的判断进行治疗。心血管疾病